Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 3Terminated 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Dermatologic 4Thoracic 1Other neoplasm 1

Conditions

Arthritis, Rheumatoid 7Melanoma 4Colitis 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Lung Neoplasms 2Inflammatory Bowel Diseases 2Inflammation 2Fatigue 2Depressive Disorder, Major 2Depression 2Colitis, Ulcerative 2Vasculitis 1Takayasu Arteritis 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Spondylitis, Ankylosing 1Skin Neoplasms 1Psoriasis 1Precancerous Conditions 1Pemphigoid, Benign Mucous Membrane 1Infections 1Hypertension 1Hepatitis C 1Hematologic Neoplasms 1Graft vs Host Disease 1Drug-Related Side Effects and Adverse Reactions 1Depressive Disorder, Treatment-Resistant 1Cytokine Release Syndrome 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Melanoma × Infliximab × Clear all
NCT05034536 2026-05-18

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

Massachusetts General Hospital

Phase 2 Active not recruiting
36 enrolled
Dermatologic

Melanoma

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

NCT00897312 2016-04-25

Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

Vanderbilt-Ingram Cancer Center

Terminated
7 enrolled
DermatologicOther neoplasm

Hepatitis C, Melanoma, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡